SABCS 2021 | Exciting trials at SABCS 2021 for pre- vs. post-menopausal hormone receptor-positive breast cancer
Meredith M. Regan, ScD, Harvard Medical School, Boston, MA, discusses what trials she is looking forward to in the field of pre- and post-menopausal hormone receptor-positive early breast cancer at SABCS 2021. Trials being presented at the congress include SOFT (NCT00066690), TEXT (NCT00066703), HOBOE (NCT00412022) and RxPONDER (NCT01272037). This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.
Disclosures
The SOFT and TEXT trials are coordinated by the International Breast Cancer Study Group (IBCSG), in collaboration with the Breast International Group (BIG), BIG cooperative groups, and US National Cancer Institute National Clinical Trials Network cooperative groups. Pfizer and Ipsen provided drug supply. IBCSG has received financial support for SOFT and TEXT conduct and long-term follow-up from Pfizer, Ipsen, DebioPharm, TerSera, AstraZeneca. Dr. Regan receives grant support from the Breast Cancer Research Foundation for SOFT and TEXT, and provides consulting or advisory role to Ipsen, DebioPharm, Tolmar.
